NasdaqGS:BIIBBiotechs
Biogen Hybrozyme Deal Links Subcutaneous Biologics Push With Valuation Gap
Biogen (NasdaqGS:BIIB) has entered an exclusive license agreement with Alteogen for its Hybrozyme (ALT-B4) technology.
The deal focuses on developing and commercializing subcutaneous versions of two biologic drugs, with an option for a third.
The alliance aims to support subcutaneous delivery formats that may improve patient convenience and treatment accessibility.
Biogen comes into this agreement with a mixed share price record, with the stock at $191.06 and a 1 year return of 36.2%, while...